SCHEMBL5340468

SCHEMBL5340468

CCCc1nc2c(N)nc(C)c(C)c2n1CCOCCNC(=O)Nc1cccnc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.42
FLT4 P35916 1/20 0.42
TLR7 Q9NYK1 5/20 0.38
TLR8 Q9NR97 2/20 0.38
KEAP1 Q14145 2/20 0.37
NFE2L2 Q16236 2/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
MEN1 O00255 1/20 0.37
CASP3 P42574 1/20 0.37
KMT2A Q03164 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
PKM P14618 1/20 0.36
CYP1A2 P05177 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5340168 0.93 CDK2 (0.42) CDK2FLT4TLR7TLR8KEAP1
SCHEMBL5337301 0.90 KEAP1 (0.40) CDK2FLT4TLR7TLR8KEAP1
SCHEMBL5333512 0.88 KEAP1 (0.41) CDK2FLT4TLR7TLR8KEAP1
SCHEMBL5339136 0.87 TLR7 (0.50) TLR7TLR8MEN1KMT2ASMN1; SMN2
SCHEMBL5346398 0.86 CDK2 (0.40) CDK2FLT4TLR7TLR8KEAP1
SCHEMBL5340187 0.84 CDK2 (0.39) CDK2FLT4TLR7TLR8KEAP1
SCHEMBL5337292 0.82 KEAP1 (0.38) CDK2FLT4KEAP1NFE2L2NPC1
SCHEMBL5341344 0.81 TLR7 (0.37) TLR7TLR8
SCHEMBL4794845 0.79 TLR7 (0.47) TLR7TLR8L3MBTL1
SCHEMBL5334340 0.79 CDK2 (0.40) CDK2FLT4TLR7TLR8KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 CDK2 1026/4885FLT4 1448/4885TLR7 33/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP CDK2 2068/4885FLT4 986/4885TLR7 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.